Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Over the last 12 months, insiders at Chimerix, Inc. have bought $0 and sold $7,673 worth of Chimerix, Inc. stock.
On average, over the past 5 years, insiders at Chimerix, Inc. have bought $174,564 and sold $7.53M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,295 shares for transaction amount of $16,522 was made by MIDDLETON FRED A (director) on 2023‑11‑17.
2024-08-08 | Sale | PRESIDENT AND CEO | 1,285 0.0014% | $0.83 | $1,065 | +7.50% | ||
2024-02-14 | Sale | PRESIDENT AND CEO | 1,744 0.0019% | $1.04 | $1,809 | -10.95% | ||
2024-02-14 | Sale | VP OF FINANCE AND ACCOUNTING | 2,660 0.003% | $1.04 | $2,777 | -10.95% | ||
2024-02-14 | Sale | CHIEF FINANCIAL OFFICER | 1,940 0.0022% | $1.04 | $2,023 | -10.95% | ||
2023-11-17 | director | 17,295 0.0192% | $0.96 | $16,522 | -1.34% | |||
2023-11-10 | director | 2,705 0.003% | $0.92 | $2,489 | +0.63% | |||
2023-09-28 | Sale | VP of Finance and Accounting | 3,610 0.0042% | $0.99 | $3,584 | -1.44% | ||
2023-09-25 | director | 20,000 0.0226% | $0.98 | $19,636 | -2.43% | |||
2023-05-18 | Chief Business Officer and CFO | 51,700 0.0598% | $1.14 | $59,150 | -10.71% | |||
2023-05-12 | Chief Executive Officer | 87,000 0.0987% | $1.12 | $97,652 | -9.82% | |||
2023-05-10 | director | 18,000 0.02% | $1.11 | $19,980 | -10.62% | |||
2023-05-08 | director | 8,750 0.0101% | $1.14 | $9,975 | -9.82% | |||
2023-03-28 | director | 20,000 0.023% | $1.21 | $24,152 | -10.92% | |||
2023-01-26 | Sale | Principal Accounting Officer | 3,230 0.0036% | $1.76 | $5,686 | -36.80% | ||
2022-09-29 | Sale | Principal Accounting Officer | 4,400 0.005% | $1.86 | $8,185 | -24.86% | ||
2022-09-29 | 20,000 0.0229% | $1.86 | $37,176 | -24.86% | ||||
2022-05-19 | 1,419 0.0015% | $2.05 | $2,909 | -16.36% | ||||
2022-05-19 | 20,000 0.0212% | $2.04 | $40,738 | -16.36% | ||||
2022-05-17 | Chief Business Officer and CFO | 15,000 0.0168% | $1.71 | $25,635 | +5.14% | |||
2022-05-17 | 10,000 0.0105% | $1.61 | $16,100 | +5.14% |
Andriole Michael T. | PRESIDENT AND CEO | 462453 0.5142% | $3.08 | 4 | 2 | +44.13% |
Jakeman David | VP OF FINANCE AND ACCOUNTING | 141232 0.157% | $3.08 | 0 | 10 | |
LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | 110999 0.1234% | $3.08 | 0 | 1 | |
CANTEX PHARMACEUTICALS, INC. | 10 percent owner | 3500000 3.8917% | $3.08 | 0 | 1 | |
Canaan VII L P | 2584990 2.8743% | $3.08 | 0 | 1 | ||
Hutton Wende S | 2584990 2.8743% | $3.08 | 0 | 1 | ||
New Leaf Ventures II, L.P. | director | 2243394 2.4944% | $3.08 | 0 | 1 | |
CHAMPSI FARAH | director | 1714330 1.9062% | $3.08 | 0 | 1 | |
NIEDEL JAMES | director | 1046082 1.1631% | $3.08 | 0 | 4 | |
Sanderling Venture Partners V, LP | 10 percent owner | 993646 1.1048% | $3.08 | 0 | 1 | |
PAPPAS ARTHUR M | director | 830695 0.9237% | $3.08 | 0 | 1 | |
Sanderling Venture Partners VI Co Investment Fund LP | 10 percent owner | 697346 0.7754% | $3.08 | 0 | 2 | |
Nichols Garrett | Chief Medical Officer | 260066 0.2892% | $3.08 | 0 | 3 | |
MARIO ERNEST | director | 108167 0.1203% | $3.08 | 19 | 9 | +22.4% |
MIDDLETON FRED A | director | 100000 0.1112% | $3.08 | 12 | 0 | +17.74% |
Berrey M Michelle | President and CEO | 99685 0.1108% | $3.08 | 5 | 0 | +24.59% |
Sherman Michael A. | Chief Executive Officer | 87000 0.0967% | $3.08 | 3 | 0 | +23.84% |
DEMSKI MARTHA J | director | 72055 0.0801% | $3.08 | 4 | 16 | <0.0001% |
Richardson Linda M | Chief Commercial Officer | 60996 0.0678% | $3.08 | 0 | 1 | |
Meyer Robert J. | director | 35150 0.0391% | $3.08 | 5 | 0 | +34.82% |
WOLLAEGER TIMOTHY | director | 10000 0.0111% | $3.08 | 1 | 3 | <0.0001% |
Machado Clarence Patrick | director | 10000 0.0111% | $3.08 | 1 | 0 | <0.0001% |
Trost Timothy W. | SVP, CFO & Secretary | 9850 0.011% | $3.08 | 0 | 14 | |
DRAKE RODMAN L | director | 3500 0.0039% | $3.08 | 5 | 0 | +42.2% |
Ricciardi Lisa | director | 1950 0.0022% | $3.08 | 1 | 0 | |
MOCH KENNETH I | President and CEO | 1313 0.0015% | $3.08 | 0 | 4 | |
LEONARD JOHN M. | director | 0 0% | $3.08 | 2 | 1 | +38.28% |
RA Capital Management, L.P. | $9.33M | 9.82 | 8.8M | 0% | +$0 | 0.01 | |
Monaco Asset Management Sam | $4.64M | 4.88 | 4.38M | 0% | +$0 | 2.13 | |
The Vanguard Group | $4.61M | 4.85 | 4.35M | 0% | +$0 | <0.0001 | |
Armistice Capital Llc | $2.4M | 2.53 | 2.26M | -12.86% | -$354,040.00 | 0.01 | |
Acadian Asset Management | $2.3M | 2.43 | 2.17M | +15.51% | +$309,325.09 | 0.01 | |
Citadel Advisors LLC | $2.01M | 2.11 | 1.9M | -8.11% | -$177,404.76 | <0.01 | |
Renaissance Technologies | $1.97M | 2.07 | 1.85M | +18.68% | +$309,307.45 | <0.01 | |
Goldman Sachs | $1.23M | 1.29 | 1.16M | -1.7% | -$21,255.12 | <0.0001 | |
Millennium Management LLC | $1.16M | 1.22 | 1.09M | +0.31% | +$3,531.92 | <0.01 | |
Bridgeway Capital Management | $1.15M | 1.21 | 1.08M | +4.81% | +$52,575.98 | 0.02 | |
BlackRock | $1.08M | 1.13 | 1.01M | -3.06% | -$33,885.02 | <0.0001 | |
Geode Capital Management | $1.03M | 1.09 | 972,799 | +6.58% | +$63,655.11 | <0.0001 | |
Acuitas Investments, LLC | $673,377.00 | 0.71 | 635,261 | +100.66% | +$337,800.97 | 0.36 | |
Northern Trust | $591,995.00 | 0.62 | 558,486 | -19.1% | -$139,740.82 | <0.0001 | |
Yakira Capital Management Inc | $538,892.00 | 0.57 | 508,389 | 0% | +$0 | 0.03 | |
Assenagon Asset Management S.A. | $481,736.00 | 0.51 | 454,468 | -9% | -$47,618.37 | <0.01 | |
Tejara Capital Ltd | $439,296.00 | 0.46 | 414,430 | -24.66% | -$143,784.83 | 0.15 | |
Adage Capital Partners Gp L L C | $424,000.00 | 0.45 | 400,000 | 0% | +$0 | <0.01 | |
BNY Mellon | $411,831.00 | 0.43 | 388,520 | -8.69% | -$39,201.96 | <0.0001 | |
D. E. Shaw & Co. | $397,104.00 | 0.42 | 374,626 | +37.95% | +$109,240.54 | <0.0001 | |
Barclays | $347,000.00 | 0.37 | 327,356 | -63.29% | -$598,219.79 | <0.0001 | |
State Street | $312,467.00 | 0.33 | 294,780 | -2.71% | -$8,692.01 | <0.0001 | |
Shay Capital Llc | $253,220.00 | 0.27 | 238,887 | +0.36% | +$915.84 | 0.04 | |
Connor Clark & Lunn Investment Management Ltd | $209,930.00 | 0.22 | 198,047 | -9.39% | -$21,759.70 | <0.0001 | |
Tealwood Asset Management | $122,970.00 | 0.13 | 116,009 | +24.34% | +$24,071.63 | 0.03 | |
Pale Fire Capital Se | $111,084.00 | 0.12 | 104,796 | -50.38% | -$112,803.32 | <0.01 | |
Credit Suisse | $99,640.00 | 0.11 | 94,000 | -29.85% | -$42,400.00 | <0.0001 | |
Verition Fund Management Llc | $84,800.00 | 0.09 | 80,000 | 0% | +$0 | <0.01 | |
Ci Private Wealth Llc | $76,379.00 | 0.08 | 72,055 | 0% | +$0 | <0.0001 | |
Vontobel Holding Ltd | $74,200.00 | 0.08 | 70,000 | 0% | +$0 | <0.01 | |
Morgan Stanley | $72,292.00 | 0.08 | 68,199 | -82.22% | -$334,397.80 | <0.0001 | |
Royal Bank of Canada | $56,000.00 | 0.06 | 52,400 | -37.81% | -$34,049.92 | <0.0001 | |
Two Sigma | $52,058.00 | 0.06 | 49,111 | +334.61% | +$40,079.92 | <0.0001 | |
Vance Wealth Inc | $50,159.00 | 0.05 | 47,320 | 0% | +$0 | 0.03 | |
Susquehanna International Group | $49,470.00 | 0.05 | 46,670 | +35.43% | +$12,941.49 | <0.0001 | |
Raymond James Associates | $45,792.00 | 0.05 | 43,200 | 0% | +$0 | <0.0001 | |
Prelude Capital | $43,884.00 | 0.05 | 41,400 | New | +$43,884.00 | <0.01 | |
Koshinski Asset Management Inc | $107,200.00 | 0.05 | 40,000 | New | +$107,200.00 | 0.01 | |
Point72 Asia Singapore Pte Ltd | $39,121.00 | 0.04 | 36,907 | New | +$39,121.00 | <0.01 | |
Xtx Topco Ltd | $38,061.00 | 0.04 | 35,907 | -56.7% | -$49,840.65 | <0.01 | |
StoneRidge Investment Partners LLC | $38,000.00 | 0.04 | 36,171 | New | +$38,000.00 | 0.01 | |
Joel Isaacson & Co., LLC | $35,662.00 | 0.04 | 33,643 | 0% | +$0 | <0.01 | |
Russell Investments Group Ltd | $34,556.00 | 0.04 | 32,600 | 0% | +$0 | <0.0001 | |
Fidelity Investments | $31,229.00 | 0.03 | 29,461 | -40.65% | -$21,384.67 | <0.0001 | |
UBS | $29,935.00 | 0.03 | 28,241 | -36.33% | -$17,081.64 | <0.0001 | |
Two Sigma Advisers LP | $28,620.00 | 0.03 | 27,000 | +21.08% | +$4,982.00 | <0.0001 | |
Toroso Investments Llc | $24,249.00 | 0.03 | 22,876 | New | +$24,249.00 | <0.0001 | |
Simplex Trading Llc | $22,000.00 | 0.02 | 21,638 | +90.16% | +$10,430.63 | <0.01 | |
Wells Fargo | $20,547.00 | 0.02 | 19,384 | +2,900.62% | +$19,862.24 | <0.0001 | |
Jane Street Capital | $18,864.00 | 0.02 | 17,796 | -90.89% | -$188,160.87 | <0.0001 |